TJM Labs Raises $10M Series A Funding

TJM Labs, a company specializing in AI-driven automation for pharmacies, has announced it has secured $10.0 million in new funding.

The capital infusion will support the company's mission to help pharmacies eliminate manual, repetitive work, thereby enhancing accuracy and throughput.

TJM Labs' solutions seamlessly handle critical tasks such as prescription intake, fax processing, demographic updates, and reporting within existing pharmacy systems, allowing staff to dedicate more time to patient care.

What distinguishes TJM Labs is its Dual-Expert Model™. This approach pairs a pharmacist with an engineer for every implementation, ensuring both clinical accuracy and technical precision.

This hands-on methodology guarantees that workflows are tailored, compliant, and resilient, moving beyond generic software solutions.

Currently, TJM Labs' AI agents support pharmacies processing tens of thousands of prescriptions each week, demonstrating the practical application of combining deep healthcare expertise with advanced technology.

This funding round represents a significant step for TJM Labs as it seeks to expand its footprint in the healthcare automation sector. The $10.

0 million investment is designated to accelerate product development, broaden its market reach, and scale its operational infrastructure to meet increasing demand.

By delivering measurable return on investment through lower costs, fewer errors, and scalable growth, TJM Labs aims to keep patient care at the center of its technological advancements.

Looking ahead, this capital positions TJM Labs to further its strategic growth initiatives and enhance its offerings.

The company plans to continue its expansion, supporting more pharmacies in optimizing their operations and improving overall efficiency, ultimately benefiting patient outcomes across the healthcare landscape.